IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients
Giorgio Pini, Maria Flora Scusa, Laura Congiu, Alberto Benincasa, Paolina Morescalchi, Ilaria Bottiglioni, Pietro Di Marco, Paolo Borelli, Ubaldo Bonuccelli, Andrea Della-Chiesa, Adriele Prina-Mello, Daniela Tropea, Giorgio Pini, Maria Flora Scusa, Laura Congiu, Alberto Benincasa, Paolina Morescalchi, Ilaria Bottiglioni, Pietro Di Marco, Paolo Borelli, Ubaldo Bonuccelli, Andrea Della-Chiesa, Adriele Prina-Mello, Daniela Tropea
Abstract
Rett syndrome (RTT) is a devastating neurodevelopmental disorder that affects one in ten thousand girls and has no cure. The majority of RTT patients display mutations in the gene that codes for the methyl-CpG-binding protein 2 (MeCP2). Clinical observations and neurobiological analysis of mouse models suggest that defects in the expression of MeCP2 protein compromise the development of the central nervous system, especially synaptic and circuit maturation. Thus, agents that promote brain development and synaptic function, such as insulin-like growth factor 1 (IGF1), are good candidates for ameliorating the symptoms of RTT. IGF1 and its active peptide, (1-3) IGF1, cross the blood brain barrier, and (1-3) IGF1 ameliorates the symptoms of RTT in a mouse model of the disease; therefore they are ideal treatments for neurodevelopmental disorders, including RTT. We performed a pilot study to establish whether there are major risks associated with IGF1 administration in RTT patients. Six young girls with classic RTT received IGF1 subcutaneous injections twice a day for six months, and they were regularly monitored by their primary care physicians and by the unit for RTT in Versilia Hospital (Italy). This study shows that there are no risks associated with IGF1 administration.
Figures
References
- Hagberg B, Witt-Engerstrom I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. American Journal of Medical Genetics. 1986;24(1):47–59.
- Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. European Child and Adolescent Psychiatry. 1997;6(1):71–74.
- Julu PO, Kerr AM, Apartopoulos F, et al. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Archives of Disease in Childhood. 2001;85(1):29–37.
- Cardoza B, Clarke A, Wilcox J, et al. Epilepsy in Rett syndrome: association between phenotype and genotype, and implications for practice. Seizure. 2011;20(8):646–649.
- Krajnc N, Župančič N, Oražem J. Epilepsy treatment in rett syndrome. Journal of Child Neurology. 2011;26(11):1429–1433.
- Haas RH, Dixon SD, Sartoris DJ, Hannessy MJ. Osteopenia in Rett syndrome. Journal of Pediatrics. 1997;131(5):771–774.
- Ariani F, Hayek G, Rondinella D, et al. FOXG1 is responsible for the congenital variant of Rett syndrome. American Journal of Human Genetics. 2008;83(1):89–93.
- Renieri A, Mari F, Mencarelli MA, et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant) Brain and Development. 2009;31(3):208–216.
- Artuso R, Mencarelli MA, Polli R, et al. Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain and Development. 2010;32(1):17–24.
- Amir RE, Van Den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2. Nature Genetics. 1999;23(2):185–188.
- Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nature Genetics. 2001;27(3):327–331.
- Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic rett syndrome. Nature Genetics. 2001;27(3):322–326.
- Johnston MV, Jeon OH, Pevsner J, Blue ME, Naidu S. Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain and Development. 2001;23(1):S206–S213.
- Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(6):2029–2034.
- Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007;315(5815):1143–1147.
- Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(6):1931–1936.
- Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006;49(3):341–348.
- Bondy CA, Cheng CM. Insulin-like growth factor-1 promotes neuronal glucose utilization during brain development and repair processes. International Review of Neurobiology. 2002;51:189–217.
- Tropea D, Kreiman G, Lyckman A, et al. Gene expression changes and molecular pathways mediating activity-dependent plasticity in visual cortex. Nature Neuroscience. 2006;9(5):660–668.
- Ciucci F, Putignano E, Baroncelli L, Landi S, Berardi N, Maffei L. Insulin-like growth factor 1 (IGF-1) mediates the effects of enriched environment (EE) on visual cortical development. PLoS One. 2007;2(5, article e475)
- Itoh M, Ide S, Takashima S, et al. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. Journal of Neuropathology and Experimental Neurology. 2007;66(2):117–123.
- Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135(5):1753–1761.
- Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. Journal of Clinical Endocrinology and Metabolism. 1996;81(11):3902–3908.
- Backeljauw PF, Underwood LE, Miras M, et al. Therapy for 6.5–7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. Journal of Clinical Endocrinology and Metabolism. 2001;86(4):1504–1510.
- Bucuvalas JC, Chernausek SD, Alfaro MP, Krug SK, Ritschel W, Wilmott RW. Effect of insulinlike growth factor-1 treatment in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition. 2001;33(5):576–581.
- Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. Journal of Clinical Endocrinology and Metabolism. 2007;92(3):902–910.
- Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clinical Endocrinology. 2008;69(3):432–435.
- Julu PO, Engerström IW, Hansen S, et al. Cardiorespiratory challenges in Rett’s syndrome. The Lancet. 2008;371(9629):1981–1983.
- Julu POO, Witt Engerström I. Assessment of the maturity-related brainstem functions reveals the heterogeneous phenotypes and facilitates clinical management of Rett syndrome. Brain and Development. 2005;27(1):S43–S53.
- Kerr AM, Nomura Y, Armstrong D, et al. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain and Development. 2001;23(4):208–211.
- Guy W. Revised (DHEW Publ No ADM 76-338) Rockville, Md, USA: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. ECDEU Assessment Manual for Psychopharmacology; pp. 218–222.
- Ishizaki A. Electroencephalographic study of the Rett syndrome with special reference to the monorhythmic theta activities in adult patients. Brain and Development. 1992;14:S31–S36.
- Ellaway CJ, Peat J, Williams K, Leonard H, Christodoulou J. Medium-term open label trial of L-carnitine in Rett syndrome. Brain and Development. 2001;23(1):S85–S89.
- Andaku DK, Mercadante MT, Schwartzman JS. Buspirone in Rett syndrome respiratory dysfunction. Brain and Development. 2005;27(6):437–438.
- Hagebeuk EEO, Koelman JHTM, Duran M, Abeling NG, Vyth A, Poll-The BT. Clinical and electroencephalographic effects of folinic acid treatment in rett syndrome patients. Journal of Child Neurology. 2011;26(6):718–723.
- Collett-Solberg PF, Misra M. The role of recombinant human insulin-like growth factor-I in treating children with short stature. Journal of Clinical Endocrinology and Metabolism. 2008;93(1):10–18.
- Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. Journal of Biological Chemistry. 2002;277(46):44005–44012.
Source: PubMed